1-3 of 3
Abraham Korenberg, MD
Close
Sort by
Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc
Journal: Blood
Blood (2016) 128 (22): 3001.
https://doi.org/10.1182/blood.V128.22.3001.3001
Published: 2016
Journal Articles

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Eldad J Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Elinor Sabbag, BSc., Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Rosa Ruchlemer, MD, Roxolyana Abdah-Bortnyak, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Netanel Horowitz, David Lavie, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc
Journal: Blood
Blood (2014) 124 (21): 4409.
https://doi.org/10.1182/blood.V124.21.4409.4409
Published: 2014
Journal Articles

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Liana Abdach, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Jacob M. Rowe, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MSc, FRCPC
Journal: Blood
Blood (2010) 116 (21): 2809.
https://doi.org/10.1182/blood.V116.21.2809.2809
Published: 2010